Wilserdly Adjuvant First Masks Metastatic Miss and $22,500 Payer Test
Regulatory Approvals

Wilserdly Adjuvant First Masks Metastatic Miss and $22,500 Payer Test

Published : 18 Nov 2026

At a Glance
IndicationER-positive, HER2-negative breast cancer
Druggiredestrant
Mechanism of ActionSelective estrogen receptor degrader (SERD)
CompanyRoche
CategoryRegulatory Milestone
Sub CategoryApproval Granted
Therapeutic AreaOncology
Approval DateNov. 16, 2026
Regulatory AgencyFDA
Approved Market/RegionU.S.
PDUFA DateDec. 18
List Price$22,500 per month
Peak Annual Sales Estimate$14 billion
Patient Population SubgroupESR1 mutations
Line of TherapyAdjuvant, Metastatic
Combination Partnereverolimus
Label WarningsSlow resting heart rate, Potential damage to developing fetus

FDA Clears Roche's Wilserdly for ER-Positive Breast Cancer

Roche's new breast cancer pill, Wilserdly (giredestrant), received FDA approval on November 16, 2026, for certain adults with ER-positive, HER2-negative breast cancer who have ESR1 mutations and have relapsed during or after hormone therapy in either the adjuvant or metastatic setting. This approval, which came ahead of the December 18 decision deadline, marks a significant launch for Roche, which anticipates Wilserdly could become its top-selling product, with peak annual sales potentially reaching $14 billion. The drug, an oral selective estrogen receptor degrader (SERD), is priced at $22,500 per month and is notable for being the only oral SERD to demonstrate benefit in the adjuvant setting.

  • Specific Indication and Patient Population: Wilserdly is approved for a targeted patient group: adults with ER-positive, HER2-negative breast cancer who possess ESR1 mutations. The treatment is indicated for those who have experienced relapse during or after hormone therapy in the post-surgery adjuvant setting, or following hormone therapy in the metastatic disease setting. This specificity addresses a critical unmet need within a defined subpopulation of breast cancer patients.
  • Novel Therapeutic Class and Market Positioning: As an oral selective estrogen receptor degrader (SERD), Wilserdly represents a newer class of breast cancer treatments aiming to improve upon older injectable hormone therapies like fulvestrant. While several oral SERDs are available, Wilserdly distinguishes itself by being the only one cleared to date that has also proven beneficial in the adjuvant setting, offering a unique competitive advantage in the evolving treatment landscape.
  • Significant Commercial Outlook and Pricing: Roche projects Wilserdly to become its top-selling product, with analysts estimating peak annual sales of up to $14 billion, largely driven by potential earlier-line use. The drug carries a list price of $22,500 per month, which is comparable to other similar breast cancer medications. This strong commercial forecast underscores the company's confidence in the drug's market potential and clinical value.
  • Regulatory Details and Safety Profile: The FDA granted approval on November 16, 2026, approximately a month ahead of the PDUFA decision deadline. The prescribing information for Wilserdly includes warnings regarding a slow resting heart rate and potential damage to a developing fetus. Despite these disclosures, the absence of a heart monitoring requirement could provide a competitive edge over some existing treatments.

Understanding the ER+/HER2- Breast Cancer Treatment Landscape

Hormone therapy, rather than chemotherapy, is recommended for hormone-receptor positive, human epidermal receptor 2 negative advanced or metastatic breast cancer according to the European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines, unless in visceral crisis in which chemotherapy is indicated. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus aromatase inhibitor (AI) is included as a standard first-line therapy, with three selective CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) approved as first-line therapy in combination with an aromatase inhibitor, or fulvestrant in the case of ribociclib. CDK4/6i plus fulvestrant and everolimus plus AI are recommended second-line options, reflecting that CDK4/6 inhibitors work best together with AI or selective estrogen receptor down-regulator (SERD) and that inhibition of the m-TOR pathway reported favorable results in the second-line setting when the PI3K-AKT-mTOR pathway is frequently overexpressed.

Post-progression management after CDK4/6 inhibitor plus endocrine therapy has shifted toward molecularly selected combination approaches rather than single-agent endocrine therapy, as endocrine monotherapy has shown limited efficacy in acquired resistance. Adding targeted agents to endocrine therapy improves progression-free survival compared with hormonal therapy alone, supporting combination regimens as the preferred strategy after CDK4/6 inhibitor progression, except in carefully selected patients with low disease burden, indolent biology, or frailty where tolerability is a major concern. In patients with ESR1-mutated tumors, next-generation oral selective estrogen receptor degraders (SERDs) are favored given their targeted mechanism, favorable tolerability, and efficacy following CDK4/6 inhibition, with elacestrant having improved progression-free survival in ESR1-mutated disease in the EMERALD trial. For tumors harboring alterations in the PIK3CA–AKT–PTEN pathway, fulvestrant combined with alpelisib remains an effective option in PIK3CA-mutated tumors, though tolerability concerns often influence long-term adherence; fulvestrant with capivasertib is increasingly preferred due to its activity across PIK3CA, AKT1, and PTEN alterations and its more manageable safety profile, with capivasertib plus fulvestrant having demonstrated significant benefit in tumors harboring AKT/PIK3CA/PTEN pathway alterations in CAPItello-291, while inavolisib plus palbociclib and fulvestrant achieved both progression-free and overall survival improvement in PIK3CA-mutated patients with early relapse in INAVO120. At present, there are just three inhibitors approved to target this pathway in patients with advanced ER-positive, HER2-negative breast cancer: everolimus (mTOR inhibitor), alpelisib (PIK3CA inhibitor), and capivasertib (AKT inhibitor).

When patients exhibit rapid progression, endocrine-independent biology, or aggressive visceral disease, early transition to antibody–drug conjugates such as trastuzumab deruxtecan or sacituzumab govitecan is used, which demonstrate superior outcomes compared with conventional chemotherapy in appropriately selected cases. Overall, an individualized, biomarker-driven approach remains central to optimizing therapeutic sequencing in advanced HR+ breast cancer, integrating next-generation sequencing-guided genomic profiling, targeted pathway therapies, and circulating tumor DNA-based proactive interventions based on resistance profiles, prior endocrine therapy response, and tumor heterogeneity.

Wilserdly's Position in the Oral SERD Landscape

Treatment of hormone receptor-positive, HER2-negative metastatic breast cancer has shifted from endocrine monotherapy to combination strategies built around first-line cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) plus endocrine therapy. The phase 3 SONIA trial randomized patients to aromatase inhibitor plus CDK4/6i first-line followed by fulvestrant second-line versus aromatase inhibitor first-line followed by fulvestrant plus CDK4/6i second-line, with median overall survival of 47.9 months (95% CI, 44.0-54.3) with first-line CDK4/6i and 48.1 months (95% CI, 44.7-52.0) with second-line CDK4/6i (hazard ratio [HR], 0.91; 95% CI, 0.77-1.07; P = .24) at median follow-up of 58.5 months (95% CI, 57.0-60.9). In early disease, monarchE with 2 years of abemaciclib and NATALEE with 3 years of ribociclib reported positive invasive disease-free survival, with abemaciclib approved for high-risk, node-positive disease, while post-CDK4/6i management has moved toward molecularly selected combination approaches rather than single-agent endocrine therapy, except in carefully selected patients with low disease burden, indolent biology, or frailty where tolerability is a major concern.

Oral selective estrogen receptor degraders (SERDs) have become a key therapeutic option after progression on endocrine therapy, particularly in ESR1-mutated disease. In SERENA-2, post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer with disease recurrence or progression on at least one line of endocrine therapy received camizestrant 75 mg, 150 mg, or fulvestrant 500 mg, with median progression-free survival of 7·2 months (90% CI 3·7-10·9) with camizestrant 75 mg, 7·7 months (5·5-12·9) with camizestrant 150 mg, and 3·7 months (2·0-6·0) with fulvestrant, and hazard ratios of 0·59 (90% CI 0·42-0·82; p=0·017) and 0·64 (0·46-0·89; p=0·0090), respectively. Elacestrant improved progression-free survival in ESR1-mutated disease in the EMERALD trial, and pooled analysis of six oral degrader monotherapy trials (n = 2,502) showed a progression-free survival benefit (HR 0.815; 95% CI 0.718-0.924; toP = 0.0014) with moderate heterogeneity (toI² = 35.2%), with a particularly robust effect in the toESR1-mutated subgroup (HR 0.617; 95% CI 0.527-0.723; toP < 0.0001) with zero heterogeneity across five independent trials (toI² = 0%). Giredestrant significantly improved invasive disease-free survival in the adjuvant lidERA trial (HR 0.70; 95% CI 0.57-0.87; toP = 0.0014) in 4,170 patients, marking the first positive adjuvant Phase III trial of any oral SERD.

Precision therapies targeting PI3K/AKT pathway alterations and broader use of antibody-drug conjugates (ADCs) and poly ADP-ribose polymerase inhibitors (PARPi) have further redefined sequencing. In the phase III CAPItello-291 trial, capivasertib in combination with fulvestrant demonstrated improved progression-free survival (PFS) (7.3 vs 3.1 months) compared with placebo-fulvestrant cohort in AKT-altered pathway patients who had progressed through prior aromatase inhibitor, with capivasertib plus fulvestrant demonstrating significant benefit in tumors harboring AKT/PIK3CA/PTEN pathway alterations, while inavolisib plus palbociclib and fulvestrant achieved both progression-free and overall survival improvement in PIK3CA-mutated patients with early relapse in INAVO120, and alpelisib plus fulvestrant established activity for PIK3CA-mutated tumors. PARP inhibitors showed targeted benefit in BRCA-mutated tumors and are available for patients with pathogenic BRCA1/2 germline mutations, while trastuzumab deruxtecan (T-DXd) demonstrated efficacy in newly emerged HER2-low and HER2-ultralow pathologic subgroups, extending median overall survival to almost 2 years, with DESTINY-Breast04 marking entry for HER2-low disease and DESTINY-Breast06 demonstrating potential for earlier and broader use including minimal HER2 expression. Proactive switching approaches in SERENA-6 and PADA-1 demonstrate that serial circulating tumor DNA (ctDNA) monitoring can detect emergent ESR1 mutations before radiographic progression, extending endocrine-based disease control by approximately 5 to 7 months.

Wilserdly's Efficacy and Differentiating Outcomes

Reported outcomes in ER-positive, HER2-negative breast cancer span first-line CDK4/6 inhibitor combinations, endocrine-based regimens, and post-CDK4/6 inhibitor targeted therapies. First-line palbociclib combinations showed prolonged progression-free survival and high response rates, while post-progression options including everolimus-based therapy and elacestrant demonstrated measurable response and survival benefits.

Regimen and Population Response Rate Progression-Free Survival Overall Survival
Fulvestrant-palbociclib vs letrozole-palbociclib in endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer 46.5% vs 50.2% 27.9 months (95% CI, 24.2-33.1 months) vs 32.8 months (95% CI, 25.8-35.9 months) (hazard ratio, 1.13; 95% CI, 0.89-1.45; P = .32) 3-year overall survival rate 79.4% vs 77.1%
Everolimus plus letrozole in HR, HER2 ABC recurring/progressing on/after prior ET 23.3% (95% CI, 13.4%-36.0%), disease-control rate in 51 (85%) patients 8.8 months (95% CI, 6.6-11.0 months) 22.9 months (95% CI, 18.5-28.9 months)
Palbociclib-fulvestrant vs placebo-fulvestrant in PALOMA-3, patients without prior chemotherapy for ABC Not reported Prolonged with palbociclib across subgroups 39.7 vs 29.5 months; hazard ratio, 0.75; 95% CI: 0.56-1.01
Palbociclib-fulvestrant vs placebo-fulvestrant in PALOMA-3, patients with prior chemotherapy for ABC Not reported Prolonged with palbociclib across subgroups 25.6 vs 26.2 months; hazard ratio, 0.91 [95% CI: 0.63-1.32]
Elacestrant vs SOC in ER+, HER2-, ESR1-mutated tumors with prior ET+CDK4/6i ≥12 months (EMERALD) Not reported 8.6 versus 1.9 months (HR, 0.41; 95% confidence interval, 0.26-0.63) Not reported
Ribociclib + letrozole vs letrozole alone (MONALEESA-2) and palbociclib + letrozole vs letrozole alone (PALOMA-2) Not reported 0.556 (0.429, 0.721) for RIBO+LET versus LET alone and 0.580 (0.460, 0.720) for PALBO+LET versus LET alone; MAIC adjustment 0.524 (0.406, 0.676) for RIBO+LET versus LET Not reported
Post-CDK4/6i: ribociclib plus ET, capivasertib plus fulvestrant, elacestrant vs conventional ET or chemotherapy Not reported HR 0.57, 95% CI 0.39-0.84; HR 0.62, 95% CI 0.51-0.75; HR 0.70, 95% CI 0.55-0.89 Not reported

Frequently Asked Questions

What is giredestrant and its mechanism of action in ER-positive breast cancer?
Giredestrant is an investigational oral selective estrogen receptor degrader (SERD) designed to inhibit estrogen receptor (ER) signaling. It functions by binding to the ER, inducing its degradation, and thereby blocking the growth-promoting effects of estrogen in ER-positive breast cancer cells. This mechanism aims to overcome resistance that can develop with other endocrine therapies.
How does giredestrant aim to address unmet needs in ER-positive, HER2-negative breast cancer treatment?
Giredestrant is being developed to offer a novel endocrine therapy option for ER-positive, HER2-negative breast cancer, particularly in settings of acquired resistance to current treatments. Its oral formulation provides a potential convenience advantage over injectable SERDs, which could improve patient adherence and treatment accessibility. It also targets ESR1 mutations, a common mechanism of resistance.
What are the potential advantages of an oral SERD like giredestrant compared to existing endocrine therapies?
Oral SERDs like giredestrant offer improved bioavailability and a more convenient administration route compared to intramuscular fulvestrant, potentially leading to more consistent drug exposure and better patient quality of life. They are designed to provide potent and complete ER degradation, which may offer a more effective blockade of estrogen signaling. This could translate to improved outcomes for patients with advanced ER-positive breast cancer.
Which patient populations are most likely to benefit from giredestrant in ER-positive, HER2-negative breast cancer?
Giredestrant is primarily being investigated for patients with ER-positive, HER2-negative breast cancer, especially those who have progressed on prior endocrine therapies. It may be particularly beneficial for patients harboring ESR1 mutations, which are known drivers of resistance to aromatase inhibitors. Its potential role in earlier lines of therapy or in combination with other targeted agents is also under evaluation.

References

  1. [1] Bhave M, Jhaveri KL et al.. Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study. Breast cancer research : BCR. 2025 Dec 21. 41423595
  2. [2] Bartsch R. ESMO 2020: highlights in breast cancer. Memo. 2021. 33968263
  3. [3] Wang J, Lamolinara A et al.. Targeting CDK4/6 in Combination with Phage-Based Anti-HER2 Vaccination Overcomes Immune Evasion and Enhances the Anticancer Response in Breast Cancer. Pharmaceutics. 2026 Jul 18. 42514958
  4. [4] Sammons S, Moore H et al.. Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer. Expert review of anticancer therapy. 2022 Aug. 35737886
  5. [5] Hernando C, Ortega-Morillo B et al.. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. International journal of molecular sciences. 2021 Jul 22. 34360578
  6. [6] Kangaspeska S, Hultsch S et al.. Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer. BMC cancer. 2016 Jul 4. 27378269
  7. [7] Parati MC, Pedersini R et al.. Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection. Breast cancer (Dove Medical Press). 2022. 35440873
  8. [8] Miah S, Bagu E et al.. Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells. BMC cancer. 2019 Jan 16. 30651078
  9. [9] Palafox M, Monserrat L et al.. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER(+) breast cancer. Nature communications. 2022 Sep 7. 36071033
  10. [10] Browne IM, Okines AFC. Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer. Cancers. 2024 Jun 18. 38927964
  11. [11] Chen B, Zhang G et al.. Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours. EBioMedicine. 2021 Sep. 34454403
  12. [12] Futamura M, Nakayama T et al.. Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316). Breast cancer (Tokyo, Japan). 2023 Nov. 37486454
  13. [13] Liu X, Qu H et al.. Efficacy of combined therapy of goserelin and letrozole on very young women with advanced breast cancer as first-line endocrine therapy. Endocrine journal. 2013. 23714650
  14. [14] Martin M, Rosca A et al.. Abemaciclib in HR+, HER2- Breast Cancer: A Narrative Review of the Clinical Evidence. Oncology and therapy. 2026 Sep. 42289616
  15. [15] Nicolò E, Gianni C et al.. Redefining Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer in the Era of Novel Antibody-Drug Conjugates. JCO oncology practice. 2026 Jan. 40359470
  16. [16] Wang T, Shen G et al.. Second-line Endocrine Therapy of Hormone Receptor-positive/HER2- negative Advanced Breast Cancer: A Systematic Review and Network Meta-analysis. Current cancer drug targets. 2023. 37026492
  17. [17] Bardia A, Cortés J et al.. Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024 Oct 1. 39087959
  18. [18] Oliveira M, Pominchuk D et al.. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial. The Lancet. Oncology. 2024 Nov. 39481395
  19. [19] Reid-Lawrence S, Mayer IA. Novel Agents for the Management of Endocrine Resistant Breast Cancer. Current breast cancer reports. 2018 Dec. 34149988
  20. [20] Sherrill B, Amonkar MM et al.. Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. The oncologist. 2010. 20798196

Contact Us

📍

Address

350 Springfield Avenue,
Suite #200 Summit, NJ 07901

✉️

For General Inquiry

info@pienomial.com

Related Posts